Physician profile
Glenn Parris
NPI 1417148834
$45,021.97
in general payments reported to CMS, 2019-2025
46 companies · $8,171 in 2025
The $8,171 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,511 · 2020: $2,567 · 2021: $11K · 2022: $5,605 · 2023: $8,490 · 2024: $5,505 · 2025: $8,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $5,788 · Education: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,013.38 |
| Consulting Fee | $5,787.50 |
| Education | $363.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $9,558.95 | 2019-2023 | Krystexxa |
| Abbvie INC. | $7,669.15 | 2019-2025 | |
| Ucb, INC. | $4,902.48 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $4,437.93 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $3,681.19 | 2019-2025 | Evenity, Enbrel, Krystexxa |
| Novartis Pharmaceuticals Corporation | $2,616.70 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,810.71 | 2020-2025 | Acthar |
| Invivyd INC | $1,549.19 | 2025 | Pemgarda |
| Glaxosmithkline, LLC. | $1,102.27 | 2019-2025 | Benlysta, Nucala |
| Genzyme Corporation | $1,055.53 | 2019-2025 | |
| Pfizer INC. | $1,037.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,031.69 | 2021-2025 | Saphnelo, Wainua |
| E.R. Squibb & Sons, L.L.C. | $749.54 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $578.48 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.89 | 2019-2024 | Ofev |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $395.01 | 2019-2025 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $249.98 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Organon LLC | $231.43 | 2021-2025 | Renflexis, Hadlima |
| Octapharma USA, INC. | $212.81 | 2022-2025 | Octagam Immune Globulin (Human) |
| Medexus Pharma, INC. | $164.41 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $160.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $149.63 | 2019-2023 | Strensiq |
| Cardinal Health 108 LLC | $148.32 | 2025 | |
| Celgene Corporation | $109.73 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $99.91 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Radius Health, INC. | $88.66 | 2019-2024 | Tymlos |
| Janssen Scientific Affairs, LLC | $85.41 | 2019-2020 | |
| Eisai INC. | $81.42 | 2021-2025 | |
| Sandoz INC. | $68.68 | 2023-2024 | Hyrimoz |
| Boston Scientific Corporation | $57.77 | 2021-2025 | General - Pain Management |
| Sobi, INC | $55.59 | 2024 | |
| Genentech USA, INC. | $47.19 | 2025 | Actemra, Gazyva |
| Cardinal Health INC | $42.84 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.20 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $40.59 | 2022-2023 | Arcalyst |
| Tersera Therapeutics LLC | $32.14 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $30.94 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $26.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $21.63 | 2025 | Tremfya |
| Csl Behring | $20.88 | 2023 | Hizentra |
| Ultragenyx Pharmaceutical INC. | $18.72 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.67 | 2024 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2021 | |
| Zyla Life Sciences, INC. | $14.77 | 2019 | |
| Hikma Pharmaceuticals USA | $14.75 | 2020 | |
| Fresenius Kabi USA, LLC | $14.29 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Parris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.